An interventional study of Serratus Posterior Superior Intercostal Plane Block With Bupivacaine and Serratus Posterior Superior Intercostal Plane Block With Saline in Heart Valve Disease and Postoperative Pain, sponsored by Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital. Recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-09.
Sponsored by Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Heart Valve Diseases with a site in Turkey — 5 open to participants now, 5 under way, none of them phase 3. Heart Valve Diseases · Turkey.
Among the 16 studies in Heart Valve Diseases with a site in Turkey, this one is one of 5 that started in 2026, is one of 7 with no phase, and was the 13th registered.
557 studies on the registry are indexed under Heart Valve Diseases; 167 are open to participants now.
Browse Heart Valve Diseases studies →5 of the 16 studies in Heart Valve Diseases with a site in Turkey are open now. Recruiting first, the newest first:
Kartal Kosuyolu Yuksek Ihtisas Education and Research Hospital · Sites in Turkey, Italy
Ages 18+
Centre Chirurgical Marie Lannelongue · Sites in Turkey, Belgium, Czechia and 9 more countries
Ages 16–110
Suleyman Demirel University · Sites in Turkey
Ages 18+
Osman Sila Aydin · Sites in Turkey
Ages 18+
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 119 Heart Valve Diseases studies recruiting now, 94 (79%) set no upper age limit and 10 (8%) stop at 75 or younger; 16 take children under 18; 15 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
First in 2008; this study’s year is marked. 5 started in 2026.
This study's planned enrollment of 90 is close to the median of 100 across 314 interventional studies indexed under Heart Valve Diseases.
Median enrollment 78 across the 8 interventional studies, 142 across the 8 observational. Of the 8 that completed or were terminated, 1 (13%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 16 have an industry lead sponsor. The 10 most frequent:
Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital is the lead sponsor of 59 studies on the registry; 24 are open to participants now.
Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital has 1 study filed under Heart Valve Diseases — fewer than ten, so there is no comparison to draw.
2 of the studies in Heart Valve Diseases with a site in Turkey that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07588230Saglik Bilimleri Universitesi Gazi Yasargil Training and Research HospitalSerratus Posterior Superior Intercostal Plane Block in Minimally Invasive Cardiac Surgery | 2026-12-25 |
| NCT07858578Osman Sila AydinTranscranial Doppler and Artificial Intelligence Prediction of Postoperative Delirium in Heart Valve Surgery | 2027-08-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 16 studies in Heart Valve Diseases with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This randomized, double-blind, placebo-controlled study aims to evaluate the effect of the serratus posterior superior intercostal plane (SPSIP) block on postoperative pain and opioid consumption in patients undergoing minimally invasive cardiac valve surgery via mini-thoracotomy.
This study is a prospective, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the analgesic efficacy of the serratus posterior superior intercostal plane (SPSIP) block in patients undergoing minimally invasive cardiac valve surgery via mini-thoracotomy. Postoperative pain following thoracic cardiac surgery may impair respiratory function and delay recovery, making effective analgesia essential.
Participants will be randomly assigned to receive an ultrasound-guided SPSIP block with either bupivacaine or normal saline under identical conditions. All patients will receive standardized general anesthesia and postoperative multimodal analgesia. Blinding will be ensured for patients and outcome assessors.
The study aims to determine whether SPSIP block with local anesthetic reduces postoperative opioid consumption and improves pain control compared to placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive an ultrasound-guided serratus posterior superior intercostal plane (SPSIP) block with bupivacaine prior to surgery, in addition to standard general anesthesia and multimodal analgesia.
Procedure: Serratus Posterior Superior Intercostal Plane Block With Bupivacaine
Participants will receive an ultrasound-guided serratus posterior superior intercostal plane (SPSIP) block with normal saline under identical conditions, in addition to standard general anesthesia and multimodal analgesia.
Procedure: Serratus Posterior Superior Intercostal Plane Block With Saline
Participants in this group will receive an ultrasound-guided serratus posterior superior intercostal plane (SPSIP) block prior to surgery using 30 mL of 0.25% bupivacaine, in addition to standard general anesthesia and multimodal analgesia.
Also known as: SPSIP Block
Participants in this group will receive an ultrasound-guided placebo block using 30 mL of normal saline under identical conditions, in addition to standard general anesthesia and multimodal analgesia.
24-hour cumulative opioid consumption
Total opioid consumption within the first 24 hours after surgery, expressed as intravenous morphine milligram equivalents (IV-MME).
Time frame: 24 hours after surgery
Postoperative pain intensity at rest (NRS)
Pain intensity at rest measured using the Numeric Rating Scale (0-10).
Time frame: 4, 6, 12, and 24 hours after surgery
Postoperative pain during movement (NRS)
Pain intensity during coughing or deep breathing measured using the Numeric Rating Scale (0-10).
Time frame: 4, 6, 12, and 24 hours after surgery
Time to first rescue analgesia
Time from the end of surgery to the first administration of rescue analgesia.
Time frame: Within 24 hours after surgery
Time to extubation
Time from the end of surgery to extubation.
Time frame: From the end of surgery until extubation, assessed up to 24 hours
Length of intensive care unit stay
Duration of stay in the intensive care unit.
Time frame: Through study completion, an average of 48 hours
Length of hospital stay
Total duration of hospitalization.
Time frame: From date of admission until discharge, up to 30 days
Inspiratory Spirometry Test
Inspiratory spirometry performance will be assessed using an incentive spirometer. Inspiratory capacity will be estimated based on the number of rising balls: 1 ball = 600 mL, 2 balls = 900 mL, and 3 balls = 1200 mL. The score ranges from a minimum of 1 ball to a maximum of 3 balls, with higher scores indicating better inspiratory function.
Time frame: 4, 6, 12, and 24 hours after surgery
Plan to share: Yes — De-identified individual participant data that underlie the results reported in this article (text, tables, figures, and appendices) will be shared.
Supporting information: Study protocol, Informed consent form
Time frame: Starting 6 months and ending 36 months following article publication.
Access criteria: Data will be available to researchers who provide a methodologically sound proposal. Proposals should be directed to acilfatma@gmail.com
No publications or documents are linked to this record.
Started May 2026 (actual). Primary completion is estimated for Dec 2026, 7 months after the start.
Of 108 non-industry interventional studies with no phase under Heart Valve Diseases, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 53. This study's planned 7 months is below that.
Counting every sponsor, half of 154 studies reached it within 30 months; a quarter within 16 and three quarters within 55.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: primary completion Oct 2026 → Dec 2026 and completion Oct 2026 → Dec 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Saglik Bilimleri Universitesi Gazi Yasargil Training and Research Hospital